Aug 12, 2024, 04:06
Akihiro Ohba: Trastuzumab Deruxtecan in HER 2–Expressing Biliary Tract Cancer
Akihiro Ohba, Medical Oncologist at Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, posted on X about recent paper by him as first author, titled “Trastuzumab Deruxtecan in HER2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial” published on Journal of Clinical Oncology.
Authors: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Takuji Okusaka.
“Trastuzumab Deruxtecan in HER 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial | Journal of Clinical Oncology.”
Source: Akihiro Ohba/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 21:37
Nov 15, 2024, 21:26
Nov 15, 2024, 21:09
Nov 15, 2024, 21:05
Nov 15, 2024, 21:03
Nov 15, 2024, 21:02
Nov 15, 2024, 20:28
Nov 15, 2024, 19:31
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45